阿尔茨海默氏症痴呆症和骨质疏松症的持续治疗使用共同数据模型之间的关联
Seonhwa Hwang1, Yong Gwon Soung2, Seong Uk Kang3
1Kangwon National University School of Medicine, Chuncheon, Korea.
Dementia and neurocognitive disorders
|November 29, 2023
概括
对阿尔茨海默氏症痴呆症 (AD) 的持续治疗可以降低骨质疏松症的风险. 这项研究发现,与持久性较差的患者相比,持久性良好的患者患有骨质疏松症的发病率较低.
科学领域:
- 老年学是一门学科.
- 神经科学是一个神经科学.
- 公共卫生 公共卫生
背景情况:
- 阿尔茨海默氏症痴呆症 (AD) 和骨质疏松症是常见的老年性疾病.
- 共同的风险因素表明,阿尔茨海默病和骨质疏松症之间存在潜在的联系.
- 了解这种联系对于全球人口老龄化至关重要.
研究的目的:
- 调查阿尔茨海默氏症痴呆症 (AD) 的持续药物治疗是否会影响骨质疏松症的发展.
- 分析AD药物治疗的坚持与患骨质疏松症的风险之间的关联.
主要方法:
- 利用韩国全国范围的健康索赔数据库,涵盖诊断,人口统计和处方.
- 将数据格式化为观察医学结果伙伴关系-共同数据模型 (OMOP-CDM) 版本5.
- 在AD药物治疗中持久性良好和持久性差的患者之间对骨质疏松症风险进行了比较分析.
主要成果:
- 包括AD药物治疗的良好和不良持久性组中的11,355人.
- 持久性较差的组表现出明显更高的骨质疏松症风险 (HR,1.20;95% CI,1.09 - 1.32;p<0.001).
结论:
- 对阿尔茨海默病抗痴呆药物治疗的良好持久性与骨质疏松症的风险明显降低有关.
- 需要进一步的研究来阐明AD和骨质疏松症之间的潜在病理生理机制.
更多相关视频
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.1K
06:59Author Spotlight: An Economic and Efficient Method for Quantitative Evaluation of Bone Microarchitecture in a Murine Osteoporosis Model
Published on: September 8, 2023
2.4K
相关概念视频
Bone Disorders
3.5K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.5K
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Alzheimer's Disease: Overview
494
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
494
Osteoclasts in Bone Remodeling
3.0K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.0K
Bone Remodeling
38.3K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.3K
